The present invention pertains to medical devices, medical device packaging, and methods for preparing and packaging medical devices. More particularly, the present invention pertains to carrier tubes for use in medical device packaging.
A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include guidewires, catheters, and the like. These devices are manufactured, packaged, and/or prepared by any one of a variety of methods. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices as well as alternative methods for manufacturing, packaging, and/or preparing medical devices.
Embodiments of the present disclosure provide design, material, and use alternatives for medical device packaging and packaging assemblies, as well as methods for preparing and packaging medical devices. An example medical device packaging assembly includes a pouch having a pocket formed therein. A carrier tube is disposed in the pocket. The carrier tube has a plurality of apertures formed therein. A medical device is disposed within the carrier tube.
An example method of preparing a medical device includes providing a carrier tube, disposing a medical device within the carrier tube to define a medical device assembly, disposing the medical device assembly within a packaging pouch, and exposing the medical device assembly to an alternative atmosphere. The carrier tube has a tube wall with a plurality of apertures formed therein.
An example time-efficient method for ethylene oxide sterilization of medical devices includes providing a carrier tube, disposing a medical device within the carrier tube to define a medical device assembly, disposing the medical device assembly within a packaging pouch, and exposing the medical device assembly to ethylene oxide for less than about 12 hours. The carrier tube has a tube wall with a plurality of apertures formed therein.
The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present invention. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.
Embodiments of the present disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:
While embodiments described herein are is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
For obvious reasons, medical devices are typically sterilized or otherwise prepared for use prior to sale. In order to preserve sterility, medical devices are usually contained within appropriate packaging that allows the sterile medical devices to be shipped to and stored by the purchaser. For example, prior to sale, medical devices such as catheters are typically sterilized and packaged. When suitably prepared, the catheters can be transported to an appropriate medical setting where they can be stored until needed for use.
Because devices like catheters may be susceptible to damage when shipped and/or stored, catheters may be disposed within a tube or shell often termed a carrier tube. The carrier tube affords the catheter some level of protection during the shipping/storage phase as well as, for example, during preparation prior to a clinical intervention. Other desirable benefits may also be achieved through the use of a carrier tube. It can be appreciated that in order to maintain the sterility of the catheter, the catheter may be disposed within the carrier tube prior to sterilization and can then be left within the packaging in order to serve its intended purpose.
Due to the relative fragility of the medical devices and the potential that the materials utilized in the manufacturing of the medical device may be adversely affected by the heat associated with traditional steam sterilization or autoclaving, other sterilization protocols are typically utilized for such devices. For example, a number of different medical devices are often sterilized using ethylene oxide sterilization techniques. Ethylene oxide sterilization techniques generally involve the exposure of the device to be sterilized to a suitable ethylene oxide environment. A number of additional conditions may also be needed such as particular relative humidity conditions, temperature, etc. in order to achieve the desired biological indication of sterility.
Because the medical devices may be packaged within a carrier tube, the time that the device and the carrier tube needs to be exposed to the ethylene oxide may be generally long. For example, the exposure time for a typical medical device to ethylene oxide may be greater than 12 hours. This may be due to the fact that in order for the sterilization medium (e.g., ethylene oxide) to reach the entire length of the medical device, the sterilization medium enters the carrier tube at one of the two ends and then diffuses to and throughout the full length of the medical device. This length may be relatively long, such as 100 to 500 centimeters (cm) or so. In addition, because diffusion may be a relatively slow process, the time required for the sterilization medium to effectively reach the entire medical device may be reasonably long. It can be appreciated that the total time required to suitably sterilize a medical device may be significant, thus consuming significant resources. For example, a typical ethylene oxide sterilization process may take in excess of 12 hours, or about 12 to 48 hours or more.
Disclosed herein are a number of medical device packages and/or packaging components, methods for packaging and/or preparing a medical device for sale, and methods for improving the shelf life of medical devices. In at least some embodiments, the packages, packaging components, and methods may allow for or otherwise include preparation steps that are shorter than typical preparation methods, thereby reducing the resources utilized. Other features and benefits are also disclosed, as discussed herein.
Carrier tube 12 may generally be configured to hold medical device 10 in a suitable configuration. In at least some embodiments, carrier tube 12 may be arranged or otherwise configured as a coil that allows medical device 10, which may have a reasonably long length, to be held in a compact configuration. The individual windings of the coil may be secured together by one or more clips 20 as is typical in the art. Other configurations for carrier tube 12 include configurations suitable for holding other medical devices.
As indicated herein, medical devices such as medical device 10 may need to be prepared and/or packaged prior to sale or use. Such preparation may include sterilization such as sterilization via an ethylene oxide sterilization technique. As illustrated in
The number, configuration, and arrangement, of apertures 22 may vary. In some embodiments, carrier tube 12 may include about 3 to 1000 apertures 22, about 10 to 500 apertures 22, about 25 to 200 apertures 22, or about 50 to 150 apertures. In one embodiment, carrier tube 12 may include about 100 apertures. It can be appreciated that the number of apertures 22 may vary.
Apertures 22 may be disposed in many suitable arrangement. For example,
The pattern or density of apertures 22 may also vary. For example, it may be desirable for apertures 22 to be arranged in a substantially constant or “regular” pattern having a substantially constant density. Alternatively, variations in the pattern and/or density are also contemplated. For example, it may be desirable for the density of apertures 22 to be generally greatest at positions furthest away from the ends of carrier tube 12 (e.g., as shown in
The shape of apertures 22 may also vary. For example, apertures 22 are illustrated as being round holes or apertures in
Carrier tube 12 may generally be formed of a polymer material. Some examples of suitable polymers include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM), for example, DELRIN® available from DuPont), polyether block ester, polyurethane, polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), high-density polyethylene (for example MARLEX® high-density polyethylene), low-density polyethylene (for example MARLEX® low-density polyethylene), linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). Carrier tube 12 may also include other materials such as metals, metal alloys, or the like.
Carrier tube 12 may be formed in a suitable manner. For example, carrier tube 12 may be formed via an extrusion process. Alternatively, carrier tube 12 may be formed via molding or other suitable process. In some embodiments, apertures 22 may be formed in carrier tube 12 by cutting, drilling, laser cutting, etching, scoring, or other suitable manners. Forming apertures 22 may generally occur after carrier tube 12 is formed. However, this is not intended to be limiting, as processes are contemplated where apertures 22 are defined in carrier tube 12 as part of the process of manufacturing carrier tube 12.
Packaging pouch 26 may include one or more additional features or structures associated therewith. For example, in some embodiments pouch 26 may have a breathable layer, for example breathable layer 30 disposed along a bottom of pouch 26 as shown in
Because carrier tube 12 includes apertures, the total time for exposure to the alternative atmosphere can be reduced (relative to the time necessary when a carrier tube lacking apertures is utilized). For example, with reference to an ethylene oxide sterilization protocol, ethylene oxide can reach the interior of carrier tube 12 at an increased rate via apertures 22 than that of a carrier tube lacking apertures. Accordingly, the total length of medical device 10 can be subjected to ethylene oxide in a shorter time frame (e.g., a shorter time frame as compared to sterilization techniques that use a carrier tube that lacks apertures). This may be beneficial for a number of reasons. For example, faster exposure (and, analogously, faster removal of the ethylene oxide) shortens the packaging process time (relative to carrier tubes lacking apertures), which can significantly impact the resources required for sterilization. Thus, the sterilization rate can be increased through the use of carrier tube 12. Other benefits may also result from the use of carrier tube 12 including, for example, quicker vacuum packaging, quicker and/or more efficient removal of deleterious materials (e.g., gases) from packaging pouch 26, improved coiling speed, allowing for the use of fewer clips 20, less resistance to irradiation cycles, etc. These are just examples.
Furthermore, exposure to an alternative atmosphere may negatively impact one or more qualities of medical device 10. For example, if medical device 10 includes a drug-eluting stent, exposure of ethylene oxide and/or humidity associated with the ethylene oxide sterilization process may cause the coating on the stent to swell or be otherwise altered. Consequently, the life cycle of the drug coating may be shortened due to exposure to ethylene oxide and/or humidity. This affect on the drug coating, ultimately, can be reflected on the shelf life of a drug-eluting stent. By reducing the time that a drug-eluting stent is exposed to ethylene oxide and/or humidity (e.g., by use of a desiccant), it may be possible to significantly reduce the amount of swelling and/or alteration of the drug coating or other moisture-sensitive coatings, which can significantly increase the shelf life of drug-eluting stents and, thus, medical devices bearing such stents. Other benefits may also be realized.
In at least some other embodiments, the general concept of adding apertures to carrier tube 12 can be applied to other structures of packaging pouch 26. For example, some packages may include a plurality of pouches (e.g., a secondary pouch disposed within a primary or high-barrier pouch). In these embodiments, the secondary pouch may include a plurality of apertures that may allow for quicker ingress/egress of gases as well as other desirable benefits.
The following example serves to exemplify some illustrative embodiments, and are not meant to be limiting.
A carrier tube was prepared with 100 apertures along the length thereof. The carrier tube was disposed in an example packaging pouch and exposed to vacuum, nitrogen flush, vacuum, nitrogen flush, vacuum, and nitrogen flush (e.g., 3 nitrogen flush cycles interspersed with vacuum). The total quantities of oxygen and water within the packaging pouch (e.g., which may also be termed the package headspace) were monitored.
Nitrogen flushing will flush out oxygen and moisture initially present in the package headspace (and do so more efficiently than within the carrier tube). Once the package is sealed, it is assumed that the concentration of oxygen and moisture is higher within the carrier tube than in the package headspace (the latter being nearly zero). Both oxygen and moisture inside the carrier tube will then begin to migrate out into the package headspace, creating an equilibrium with the entire package.
The quantities of oxygen and water within the packaging pouch was measured over 1,440 hours in a packaging pouch with either a carrier tube lacking apertures (e.g., the “standard” carrier tube) or a carrier tube with apertures (e.g., the “holed” carrier tube). The amount of oxygen detected in the packaging pouch over time is shown graphically in
Because the initial headspace concentration of oxygen and water was different for the carrier tube with apertures than for the carrier tube lacking apertures,
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
Number | Name | Date | Kind |
---|---|---|---|
3754700 | Bonk | Aug 1973 | A |
3851814 | Stage | Dec 1974 | A |
3926311 | Laske | Dec 1975 | A |
3942634 | Gandi et al. | Mar 1976 | A |
4154342 | Wallace | May 1979 | A |
4216860 | Heimann | Aug 1980 | A |
4730726 | Holzwarth | Mar 1988 | A |
4861632 | Caggiano | Aug 1989 | A |
4941308 | Grabenkort et al. | Jul 1990 | A |
5217114 | Gadberry et al. | Jun 1993 | A |
5577368 | Hamilton et al. | Nov 1996 | A |
5590778 | Dutchik | Jan 1997 | A |
5620656 | Wensky et al. | Apr 1997 | A |
5681322 | Hartigan, Jr. | Oct 1997 | A |
5690623 | Lenz | Nov 1997 | A |
5730150 | Peppel et al. | Mar 1998 | A |
5848691 | Morris et al. | Dec 1998 | A |
5874045 | Chisum | Feb 1999 | A |
5928516 | Hopkins et al. | Jul 1999 | A |
5935501 | Andrews et al. | Aug 1999 | A |
6065597 | Pettersson et al. | May 2000 | A |
6174934 | Sun | Jan 2001 | B1 |
6312646 | Kowanko | Nov 2001 | B2 |
6423226 | Hopkins et al. | Jul 2002 | B1 |
6585702 | Brunel | Jul 2003 | B1 |
6871740 | Cao | Mar 2005 | B1 |
6875400 | Speer | Apr 2005 | B2 |
7000770 | Clarke | Feb 2006 | B2 |
7040485 | Gupta | May 2006 | B2 |
7108682 | Duffy et al. | Sep 2006 | B2 |
7178555 | Engel | Feb 2007 | B2 |
7211308 | Rhee | May 2007 | B2 |
7234597 | Rowe et al. | Jun 2007 | B2 |
7261205 | Cervantes | Aug 2007 | B2 |
7303734 | Moriyama | Dec 2007 | B2 |
7337593 | Blum | Mar 2008 | B2 |
7353946 | Cervantes | Apr 2008 | B2 |
7631760 | Guelzow et al. | Dec 2009 | B2 |
7694810 | Barry et al. | Apr 2010 | B1 |
7694813 | Shalaby | Apr 2010 | B2 |
7762044 | Clarke et al. | Jul 2010 | B2 |
7776003 | Zauner | Aug 2010 | B2 |
7909249 | Bagozzi et al. | Mar 2011 | B2 |
20020015673 | Moriyama | Feb 2002 | A1 |
20030008152 | Tsai | Jan 2003 | A1 |
20030178329 | Furukawa | Sep 2003 | A1 |
20040155053 | Sanchez | Aug 2004 | A1 |
20040187438 | Clarke | Sep 2004 | A1 |
20040243214 | Farrell | Dec 2004 | A1 |
20050109648 | Kerzman et al. | May 2005 | A1 |
20050143803 | Watson | Jun 2005 | A1 |
20050199521 | Givens | Sep 2005 | A1 |
20050218022 | Cervantes | Oct 2005 | A1 |
20050278012 | Vonderwalde | Dec 2005 | A1 |
20060016708 | Ingraham | Jan 2006 | A1 |
20060086254 | Fudge et al. | Apr 2006 | A1 |
20060260967 | Clarke et al. | Nov 2006 | A1 |
20070014951 | Soerensen et al. | Jan 2007 | A1 |
20070084144 | Labrecque et al. | Apr 2007 | A1 |
20070092167 | Tilman et al. | Apr 2007 | A1 |
20090269444 | Thomas, Jr. | Oct 2009 | A1 |
20090314676 | Peck et al. | Dec 2009 | A1 |
20110079525 | Peck et al. | Apr 2011 | A1 |
Number | Date | Country |
---|---|---|
0492399 | Jul 1992 | EP |
0629415 | Dec 1994 | EP |
0782868 | Jul 1997 | EP |
0944474 | Oct 2002 | EP |
9903754 | Jan 1999 | WO |
2004066876 | Aug 2004 | WO |
2004071308 | Aug 2004 | WO |
2005058586 | Jun 2005 | WO |
2005058586 | May 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20120037525 A1 | Feb 2012 | US |